Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
ARGX
ARGX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest ARGX ETF News Today | Earnings, Events & Price Alerts
ARGX News
Significant Milestones in Biotech Sector This Week
5d ago
NASDAQ.COM
Argenx Reports Strong Q4 Results and Positive Phase 3 Study Outcomes
5d ago
Benzinga
Argenx Reports Positive Phase 3 Results for VYVGART in Ocular Myasthenia Gravis
6d ago
Benzinga
Argenx Reports Positive Phase 3 Results for Vyvgart in Eye Disease
6d ago
Newsfilter
argenx SE Q4 Earnings Beat Expectations with Strong Revenue Growth
6d ago
seekingalpha
argenx Reports $4.2 Billion in 2025 Net Sales, Achieving First Year of Profitability
6d ago
Newsfilter
argenx Reports Positive Results for VYVGART in Ocular Myasthenia Gravis Treatment
6d ago
Newsfilter
argenx SE to Announce Q4 Earnings on February 26
Feb 25 2026
seekingalpha
argenx COO to Participate in Healthcare Conference
Feb 23 2026
Newsfilter
Argenx SE Rated as One of the Best Growth Stocks for the Next Decade
Feb 04 2026
Yahoo Finance
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
Jan 14 2026
NASDAQ.COM
Argenx (ARGX) Receives FDA Priority Review for Vyvgart Expansion Application
Jan 13 2026
seekingalpha
Argenx's VYVGART Receives FDA Priority Review for First Treatment of AChR-Ab Seronegative MG
Jan 13 2026
NASDAQ.COM
Argenx (ARGX) Files Supplemental Biologics License Application for Vyvgart
Jan 13 2026
Yahoo Finance
argenx Submits VYVGART sBLA for FDA Priority Review, Target Date May 10, 2026
Jan 13 2026
Globenewswire
argenx Files for Priority Review of VYVGART for gMG Treatment with FDA
Jan 13 2026
Newsfilter
Show More News
